Literature DB >> 9228660

Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate.

M R Zalutsky1, M G Stabin, R H Larsen, D D Bigner.   

Abstract

A paired-label study was performed in athymic mice bearing subcutaneous D-54 MG human glioma xenografts to compare the localization of human/mouse anti-tenascin chimeric antibody 81C6 labeled by reaction with N-succinimidyl 3-[211At]astatobenzoate and N-succinimidyl 3-[131I]iodobenzoate. Over the 48-h observation period, the distribution of 211At- and 131I-labeled antibody were quite similar in tumor and normal tissues except stomach. These data were used to calculate human radiation doses for both intravenously and intrathecal administered 211At-labeled chimeric 81C6 using a quality factor of 5 for alpha-emissions.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9228660     DOI： 10.1016/s0969-8051(97)00060-7

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN： 0969-8051            Impact factor:   2.408


  15 in total

Review 1.  Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.

Authors:  Michael R Zalutsky; David A Reardon; Oscar R Pozzi; Ganesan Vaidyanathan; Darell D Bigner
Journal:  Nucl Med Biol       Date:  2007-05-11       Impact factor: 2.408

2.  Shelf-life of ɛ-lysyl-3-(trimethylstannyl)benzamide immunoconjugates, precursors for 211At labeling of antibodies.

Authors:  Emma Aneheim; Jenny Halleröd; Per Albertsson; Holger Jensen; Stellan Holgersson; Sture Lindegren
Journal:  Cancer Biother Radiopharm       Date:  2015-01-14       Impact factor: 3.099

3.  Labeling Monoclonal Antibody with α-emitting 211At at High Activity Levels via a Tin Precursor.

Authors:  Ganesan Vaidyanathan; Oscar R Pozzi; Jaeyeon Choi; Xiao-Guang Zhao; Shawn Murphy; Michael R Zalutsky
Journal:  Cancer Biother Radiopharm       Date:  2020-02-28       Impact factor: 3.099

4.  Astatine Radiopharmaceuticals: Prospects and Problems.

Authors:  Ganesan Vaidyanathan; Michael R Zalutsky
Journal:  Curr Radiopharm       Date:  2008-09-01

Review 5.  Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy.

Authors:  François Guérard; Jean-François Gestin; Martin W Brechbiel
Journal:  Cancer Biother Radiopharm       Date:  2012-10-17       Impact factor: 3.099

6.  Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.

Authors:  Michael R Zalutsky; David A Reardon; Gamal Akabani; R Edward Coleman; Allan H Friedman; Henry S Friedman; Roger E McLendon; Terence Z Wong; Darell D Bigner
Journal:  J Nucl Med       Date:  2007-12-12       Impact factor: 10.057

7.  Preparation of Rh[16aneS4-diol](211)At and Ir[16aneS4-diol](211)At complexes as potential precursors for astatine radiopharmaceuticals. Part I: Synthesis.

Authors:  Marek Pruszyński; Aleksander Bilewicz; Michael R Zalutsky
Journal:  Bioconjug Chem       Date:  2008-03-14       Impact factor: 4.774

8.  Reagents for astatination of biomolecules. 4. Comparison of maleimido-closo-decaborate(2-) and meta-[(211)At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [(211)At]astatine.

Authors:  D Scott Wilbur; Monica S Thakar; Donald K Hamlin; Erlinda B Santos; Ming-Kuan Chyan; Hirohisa Nakamae; John M Pagel; Oliver W Press; Brenda M Sandmaier
Journal:  Bioconjug Chem       Date:  2009-09-04       Impact factor: 4.774

Review 9.  Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".

Authors:  Romain Eychenne; Michel Chérel; Férid Haddad; François Guérard; Jean-François Gestin
Journal:  Pharmaceutics       Date:  2021-06-18       Impact factor: 6.321

10.  Comparative studies on the therapeutic benefit of targeted α-particle radiation therapy for the treatment of disseminated intraperitoneal disease.

Authors:  Diane E Milenic; Kwamena E Baidoo; Young-Seung Kim; Rachel Barkley; Martin W Brechbiel
Journal:  Dalton Trans       Date:  2017-10-31       Impact factor: 4.390
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.